Kessel A, Kohli M, Swami U. Current management of metastatic castration-sensitive prostate cancer. Cancer Treat Res Commun. 2021;28:100384.
Hahn AW, Higano CS, Taplin M-E, Ryan CJ, Agarwal N. Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment. Am Soc Clin Oncol Educ B. 2018;38:363–71.
Iacovelli R, Ciccarese C, Mosillo C, Bimbatti D, Fantinel E, Stefani L, et al. Comparison between prognostic classifications in de novo metastatic hormone sensitive prostate cancer. Target Oncol. 2018;13:649–55.
Roy S, Morgan SC. Who dies from prostate cancer? An analysis of the surveillance, epidemiology and end results database. Clin Oncol. 2019;31:630–6.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121–31.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51.
Fizazi K, Tran NP, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700.
Chi KN, Agarwal N, Bjartell A, Chung BH, Gomes AJPDS, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2019;381:13–24.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial. J Clin Oncol. 2018;36:1080–7.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–18.
Rucci N, Angelucci A. Prostate cancer and bone: the elective affinities. Biomed Res Int. 2014; 2014. https://doi.org/10.1155/2014/167035.
Muralidharan A, Smith MT. Pathobiology and management of prostate cancer-induced bone pain: Recent insights and future treatments. Inflammopharmacology. 2013;21:339–63.
Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29:2200–7.
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105:1729–37.
Cella D, Traina S, Li T, Johnson K, Ho KF, Molina A, et al. Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. Ann Oncol. 2018;29:392–7.
Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008;26:2544–9.
Iacovelli R, Ciccarese C, Caffo O, De Giorgi U, Tucci M, Mosillo C, et al. The prognostic value of pain in castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:654–60.
Halabi S, Li C, Luo S. Developing and validating risk assessment models of clinical outcomes in modern oncology. JCO Precis Oncol. 2019: 1–12.
Jenkins DA, Sperrin M, Martin GP, Peek N. Dynamic models to predict health outcomes: current status and methodological challenges. Diagnostic Progn Res. 2018;2:1–9.
Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018;19:194–206.
Cleeland CS. The Brief Pain Inventory User Guide. www.mdanderson.org (accessed 1 Feb 2022).
Cook KF, Schalet BD, Kallen MA, Rutsohn JP, Cella D. Establishing a common metric for self-reported pain: linking BPI Pain Interference and SF-36 Bodily Pain Subscale scores to the PROMIS Pain Interference metric. Qual Life Res. 2015;24:2305–18.
Rizopoulos D, Molenberghs G, Lesaffre EMEH. Dynamic predictions with timedependent covariates in survival analysis using joint modeling and landmarking. Biom J. 2017;59:1261–76.
Rizopoulos, D. Joint Models for Longitudinal and Time-to-Event Data: with Applicationsin R. Boca Raton: Chapman and Hall/CRC. 2012.
Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient’s experience. Clin Cancer Res. 2006;12:6236s–6242s.
N J. Bone metastases: approaches to management. Semin Oncol. 2001;28:28–34.
McPherson CJ, Hadjistavropoulos T, Lobchuk MM, Kilgour KN. Cancer-related pain in older adults receiving palliative care: patient and family caregiver perspectives on the experience of pain. Pain Res Manag J Can Pain Soc. 2013;18:293.
Cohen SR, Mount BM. Pain with life-threatening illness: its perception and control are inextricably linked with quality of life. Pain Res Manag. 2000;5:971487.
Molloy NH, Read DE, Gorman AM. Nerve growth factor in cancer cell death and survival. Cancers. 2011;3:510.
Di Donato M., Cernera G, Migliaccio A, Castoria G. Nerve growth factor induces proliferation and aggressiveness in prostate cancer cells. Cancers. 2019;11. https://doi.org/10.3390/CANCERS11060784.
Chen W-Y, Wen Y-C, Lin S-R, Yeh H-L, Jiang K-C, Chen W-H, et al. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. Commun Biol. 2021;4:1–14. 2021 41
Delanoy N, Robbrecht D, Fizazi K, Mercier F, Sartor O, De Wit R, et al. Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA. Ann Oncol. 2019;30:v335–v336.
Armstrong AJ, Garrett-Mayer E, Yang YCO, Carducci MA, Tannock I, De Wit R, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965–70.
Dómine Gómez M, Díaz Fernández N, Cantos Sánchez de Ibargüen B, Zugazabeitia Olabarría L, Martínez Lozano J, Poza de Celis R, et al. Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting. Adv Ther. 2016;34:136–47.
Lin CC, Lai YL, Ward SE. Effect of cancer pain on performance status, mood states, and level of hope among Taiwanese cancer patients. J Pain Symptom Manag. 2003;25:29–37.
Haus R, Janssen S, Schild SE, Rades D. Eastern Cooperative Oncology Group performance score is associated with survival after radiotherapy of bone metastases from prostate cancer. Vivo. 2020;34:679–82.
Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin M-E, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2021;39:1274–305.
Fizazi K, Galceran JC, Foulon S, Roubaud G, McDermott R, Fléchon A, et al. A phase III trial with a 2 × 2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. Ann Oncol. 2021;32:S1299.
Asghari A, Nicholas MK. Pain self-efficacy beliefs and pain behaviour. A prospective study. Pain. 2001;94:85–100.
Asghari A, Nicholas MK. Personality and pain-related beliefs/coping strategies: a prospective study. Clin J Pain. 2006;22:10–18.
Czerw AI, Religioni U, Deptała A, Fronczak A. Pain, acceptance of illness, adjustment to life with cancer and coping strategies in prostate cancer patients. Arch Med Sci. 2017;13:1459.